Exhibit 99
FOR IMMEDIATE RELEASE:

                       LIFEPOINT SEEKS ADDITIONAL FUNDING

ONTARIO, CALIFORNIA - January 31, 2003 -LifePoint, Inc. (AMEX: LFP), a leader in
non-invasive drug and alcohol diagnostic technologies and solutions, announced
today that the Company plans to raise between $7 and $10 million in funding.

In November 2002, LifePoint closed on the initial $2.5 million tranche of a $10
million working capital line; however, the Company believes that due to a change
in internal investment parameters and management, the investor has decided not
to extend the additional $7.5 million available under the credit facility. The
existing $2.5 million already drawn under the credit facility will remain in
place in accordance with its terms. LifePoint is seeking alternative financing
to replace the additional funds no longer available under this credit facility.

LifePoint had been reducing its cash burn through the natural transition from an
R&D to a manufacturing, sales and marketing focus, and through that process has
reduced its monthly cash burn from $1.1 million during the quarter ended
September 30, 2002, down to $0.7 million in December 2002. Additional reductions
have or are being implemented to bring the monthly cash burn down to under $0.4
million. The Company currently believes that its sales for the quarter ended
December 31, 2002, which have not yet been audited nor reviewed by the outside
auditors, were flat compared to the previous quarter, but represented only a
portion of the instrument shipments made during the quarter. In addition to the
instruments sold, instruments were shipped for field evaluations, marketing
pilots, and contingent customer sales not yet recorded in revenues. During these
evaluations, the test system has generally performed as expected.

LifePoint is still awaiting clearance of the IMPACT(R) TEST SYSTEM from the FDA.
LifePoint has just received a request for clarification from the FDA, and is in
the process of responding to that request. LifePoint continues to expect
clearance this quarter.

"We are disappointed that the credit facility from our investor was not
extended; however, LifePoint previously has been able to obtain financing during
difficult times. At this time, LifePoint has numerous patents that have issued,
manufactures a stable product, and has received early customer acceptance, which
will be further validated with FDA clearance. We have been pursuing parallel
paths to secure capital, and have several potential interested investors at this
time."



As of December 31, 2002 the Company had a cash balance
of $1.2 million. The Company has limited cash resources available to fund
operations. There can be no assurance that the Company will be able to obtain
the additional funding that it is seeking. If the Company is unable to obtain
additional funding, the Company may not be able to continue to operate its
business and will consider other available strategic alternatives.


ABOUT LIFEPOINT, INC.

LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and
solutions, has developed, manufactures and markets the IMPACT TEST SYSTEM - a
rapid diagnostic testing, screening and drug monitoring device for use in law
enforcement and the workplace, and in the future, pending FDA approval,
ambulances, pharmacies, and home healthcare markets. LifePoint's patented and
proprietary technologies for the use of saliva as a non-invasive,
blood-comparable test specimen, used in conjunction with the flow immunosensor
technology licensed from the United States Navy, have allowed LifePoint to
develop a broadly applicable, rapid, on-site diagnostic test system. The first
product simultaneously detects drugs of abuse and alcohol. The initial three
target markets - law enforcement, industrial workplace and medical emergency
room - are estimated to be over $1.6 billion in total opportunity.

This press release contains forward-looking statements regarding future events
and the future performance of LifePoint, Inc. that involve risks and
uncertainties that could cause actual results to differ materially. These risks
include, but are not limited to the ability to obtain additional financing, the
actual amount of revenues for the quarter may differ materially from the
Company's estimates, FDA 510(k) clearance in medical markets, dependence on
third parties for certain marketing efforts, and market acceptance. These risks
are described in further detail in the Company's reports filed with the
Securities and Exchange Commission.

LIFEPOINT(R)and IMPACT(R)are trademarks of LifePoint, Inc.

CONTACTS:
LifePoint, Inc.
Linda H. Masterson, CEO & President
(909) 418-3000 x 400
e-mail: LifePoint@LFPT.com
Web site: www.LifePointInc.com.

INVESTORS:
Cameron Associates
Lester Rosenkrantz
(212) 245-8800 ext. 212


                                      # # #